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Abstract
The extracellular levels of the neurotransmitter glycine in the brain are tightly regulated
by the high-affinity glycine transporter 1 (GlyT1) and the clearance of glycine depends on its
rate of transport and the levels of cell surface GlyT1. Over the past years, it has been shown that
PKC activation diminishes the activity and promoted phosphorylation of several neurotransmitter
transporters including the dopamine, serotonin and norepinephrine transporters however, its role
is unknown for the glycine transporter. To get insights into the role of PKC activation on GlyT1
regulation, we used three N-terminus GlyT1 isoforms stably expressed in porcine aortic
endothelial (PAE) cells and assaying for [32P]-orthophosphate metabolic labeling. We
demonstrated that the isoforms GlyT1a, GlyT1b, and GlyT1c were constitutively
phosphorylated, and that phosphorylation was dramatically enhanced, in a time-dependent
fashion, after PKC activation by phorbol ester (PMA). The phosphorylation was PKC-dependent,
since pre-incubation of the cells with bisindolylmaleimide I (BIM), a selective PKC inhibitor,
abolished the phorbol ester-induced phosphorylation. Moreover, blotting of a purified GlyT1
fraction with specific antibodies to phosphorylated tyrosine residues did not yield any signal that
could correspond to GlyT1 phosphorylation, suggesting that the phosphorylation occurs at serine
and/or threonine residues. In addition, by using more specific inhibitors to the different PKC
isoenzymes, we were able to determine the PKC isoenzyme(s) involved in downregulation of
glycine uptake and GlyT1 phosphorylation. Specifically, we found that pre-incubation of the
cells with the selective PKCα/β inhibitor Gö6976 completely abolished the effect of phorbol
ester on uptake and phosphorylation. On the other hand, incubation with either selective PKCβ
inhibitors (PKCβ inhibitor or LY333531) prevented the PKC-dependent phosphorylation of
GlyT1 without affecting the downregulation triggered by PMA. Taken together, this data suggest
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that conventional PKCα/β regulates the uptake of glycine and probably its efflux, whereas PKCβ
is responsible for GlyT1 phosphorylation.
In order to determine the sites of phosphorylation, we mutated all the threonine and serine
residues found at either, the N- or C-terminus to alanine residues. Incubation of cells stably
expressing the GlyT1 N- or C-mutants with PMA triggered phosphorylation at similar levels to
those obtained for the wild-type transporter, suggesting that both N- and C-terminal tails in the
GlyT1 are phosphorylated. Although the results demonstrate GlyT1 phosphorylation, the role of
this modification still remains to be elucidated.
Additionally, in order to obtain structural information about the potential glycine-binding site, a
model of three-dimensional structure of the GlyT1 was built based on the atomic coordinates of
the related bacterial leucine transporter (LeuT). The resulting model showed a helical bundle and
a substrate binding-pocket similar to the LeuT. This model was used to analyze the reactivity of
cysteine residues in the GlyT1 to fluorescently-labeled maleimides. The reactivity of the cysteine
residues was assayed by incubation of cells expressing the wild-type transporter with the
hydrophilic fluorescein maleimide resulting in labeling of transporter without any significant
effect on glycine uptake. By contrast, incubation with either hydrophobic pyrenyl or coumarin
maleimides resulted in rapid inhibition of glycine uptake. These results suggest that inhibition of
the activity could be due a modification of a cysteine residue(s) lying in or near to the glycinebinding site. In agreement with this hypothesis, our model suggests the presence of the Cys-152
in the putative substrate-pocket. Further mutagenesis analysis combined with chemical
modification should pave the way for studying the glycine-binding site and translocation
pathway in the GlyT1.
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Chapter 1: Introduction
1.1 Glycine and Glycine Transporter Type 1
The amino acid glycine is the simplest amino acid out of the 20 found in proteins and
traditionally grouped into the non-essential category for humans (Nelson and Cox, 2005). Earlier
studies by Aprison and Werman (1965) showed that glycine acts as a postsynaptic inhibitory
neurotransmitter in the spinal cord of the cat, and since then, glycine has been known as one of
the major inhibitory neurotransmitters. Glycine (Gly) binds to the glycine receptor (GlyR), a
ligand-gated Cl- channel found in neurons from the spinal cord and brain stem, resulting in
increased Cl- permeability (Davidoff et al., 1969; Aprison et al., 1969; Curtis et al., 1971). Gly is
also known to be an excitatory neurotransmitter because, along with glutamate, it co-actives the
N-methyl-D-aspartic acid (NMDA) receptor (Johnson and Ascher, 1987). The NMDA receptor
belongs to a sub-type of excitatory ligand-gated ion channel that requires glutamate, glycine and
postsynaptic membrane depolarization for channel opening. Activation of NMDA receptor leads
to a flow of mostly calcium ions through the channel (Nowak et al., 1984). The information
obtained for glycine during the 1970’s and 1980’s led to the idea of the presence of a specific
and high-affinity glycine transporter. Several groups showed the existence of glycine transport
coupled to Na+/Cl- in brain membranes, suggesting the presence of a protein that was acting as a
specific and high-affinity carrier (Mayor et al., 1981). Later, the glycine transporter 1 (GlyT1)
was purified, reconstituted, and 5 isoforms were cloned (isoforms a, b, c, d and f) (LopezCorcuera and Aragon 1989; Lopez-Corcuera et al., 1991; Guastela et al., 1992; Liu et al., 1992;
Borowsky et al. 1993; Kim et al., 1994; Borowsky et al. 1998).
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GlyT1 is expressed mainly in the spinal cord, brainstem, cerebellum and to a low degree
in the olfactory bulb and midbrain. Regarding cell type, GlyT1 is believed to be expressed in
glial cells and glycinergic neurons. However, in the retina, GlyT1 was found only in the
amacrine neurons (Zafra et al., 1995). It was not until the discovery of GlyT1 inhibitors, that the
modulation of NMDA receptor by GlyT1 was demonstrated (Atkinson et al., 2001; Aubrey and
Vandenberg, 2001; Martina et al., 2004). The essential role of GlyT1 was observed after a geneknockout mouse was produced; the results showed that the knockout mice (GlyT1-/-) died within
the first day of birth, by impairment of several motor and respiratory defects. The synaptosomal
preparations from the frontal brain, brain stem and spinal cord of the homozygote (GlyT1-/-) mice
shows significantly impaired glycine uptake as compared to results obtained from the membrane
preparations of the heterozygote (GlyT1+/-) or wild-type mice. Interestingly, the heterozygote
gene-knockout mouse showed higher memory retention and 50% reduction in glycine uptake
when compared to the wild-type, in membrane preparations from frontal brain, brain stem and
spinal cord, (Gomeza et al., 2003; Tsai et al., 2004; Gabernet et al., 2005). Electrophysiological
analysis of glutamatergic fibers in the GlyT1+/- mouse revealed that the reduced expression of
GlyT1 was not enough for maintaining sub-saturating concentrations of extracellular glycine,
and therefore resulting in potentiation of the NMDA receptor activity.
The NMDA receptors are glutamate-gated ion channels composed of assemblies of an
obligatory NR1 subunit and NR2 subunits, where the glutamate binding domain is formed at the
junction of NR1 and NR2 subunits. A great amount of pharmacological, anatomical and
postmortem studies suggest that the dramatic alterations of glutamatergic neurotransmission in
patients with schizophrenia, that are primarily due to a reduced number of functional glutamate
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receptors (Glutamate hypo-function hypothesis). The NMDA receptor has attracted the most
attention because cognitive functions depend on the plasticity mediated by the NMDA receptors.
As highlighted above, in addition to glutamate, the NMDA receptor requires glycine as
an obligatory co-agonist to allow full activation of the receptor and its binding site is located on
the NR1 subunit. Given the fact that direct agonist of the glutamate-binding site may induce
excess activation and neurotoxicity, the glycine-binding site and the glycine transporter have
been primarily the promising target for drug development in schizophrenia treatment. Given the
fact that glycine is required for activation of the receptor, the role of the glycine transporter is
critical as a modulator of the glycine concentration at the synaptic cleft. However, how the
transporter is regulated remains poorly understood.
The GlyT1 belongs to the solute carrier 6 (SLC6) family of transporters that includes
transporters for GABA, SER, DA, NE, proline, and orphan transporters of unknown substrates
(Torres et al., 2003). Specifically, GlyT1 is encoded in humans by the gene SLC6A9 and has
been mapped to chromosome 1 p31.3 in the genome, as well in the mouse genome to
chromosome 4 (Kim et al. 1994; Jones et al. 1995). In the brain, glycine is transported from
synaptic cleft back into the cytoplasm of the glial cell via GlyT1 in a Na+/Cl- dependent fashion
with a stoichiometry of 2 Na+/1 Cl-/1 glycine (Aragón et al., 1987). Therefore, this activity
depends on the Na+ concentration gradient generated by the plasma membrane Na+/K+-ATPase.
The rat-GlyT1 gene encodes for two amino-terminals splicing variants, the GlyT1a and GlyT1b
isoforms (Borowsky et al., 1993; Borowsky and Hoffman, 1998). Later, another splicing variant,
the GlyT1c, was discovered for the human-GlyT1 gene and characterized by the presence of
additional 54 residues in the amino-terminus (Kim et al., 1994).
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Structurally, the GlyT1 isoforms share a similar topology with other members of the
SLC6 transporters. They span the plasma membrane by 12 transmembrane domains connected by
six extracellular and five intracellular loops (Figure 1). A large extracellular loop between
segments III and IV contains multiple N-glycosylation sites, and mutations at these glycosylation
sites and treatment with tunicamycin or with N-glycosidase F demonstrated that N-glycosylation
is not essential for glycine uptake, but is critical for the proper folding and trafficking of the
transporter to the cell membrane (Olivares et al., 1997).

Figure 1. Topology of the GlyT1. The 12 transmembrane domains
and N-glycosylations are shown in gray and blue respectively.

Given the critical role of the GlyT1 in neurotransmission, the activity should be tightly
regulated in order to control the levels of extracellular glycine and termination of
neurotransmission. Over the last two decades of investigations, it has been shown that activation
of protein kinase C (PKC) by phorbol ester (PMA), an analog of the natural activator
diacylglycerol (DAG) (Figure 2), decreases [3H]glycine uptake mediated by GlyT1b. This
reduction in the activity has been attributed to the endocytosis of the transporter (Sato et al.,
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1995), and the reduction of glycine uptake can be prevented by pre-incubation with the PKC
inhibitor bisindolylmaleimide I (BIM). Bisindolylmaleimide I is a staurosporine derivative
compound that selectively inhibits PKC with a Ki = 14 ± 3 nM (Toullec et al., 1991). The
downregulation mechanism by PMA has already
been studied for other transporters such as DAT

PMA

DAG

or NET, and different inhibition potency found
among different cell types was attributed to
MKP3 expression which is a phosphatase
responsible for the regulation of the dynamindependent endocytosis of DAT (Mortensen et al.,

Figure 2. The artificial and natural co-factors of PKC.
Chemicals structures for phorbol 12-myristate 13-acetate
(PMA) and diacylglycerol (DAG) are shown. R1 and R2 are
fatty acids.

2008). Studies on DAT showed that the amount of transporters at the cell surface is determined
by the relative rates of its internalization and recycling via clathrin, explaining the decrease in
dopamine uptake after PMA treatment (Daniels and Amara, 1999; Miranda et al., 2007). The
same phenomenon seems to occur for GlyT1, and a similar explanation has been given for the
reduction of glycine uptake after PMA treatment. Although PKC is a critical player in the
regulation of GlyT1 activity, the PKC isoenzyme and the resulting modifications of transporter
triggered by PKC remains to be elucidated. A brief introduction of PKC and its role in GlyT1
modulation is described in the following section.

1.2 Protein Kinase C
The process of phosphorylation involves the transfer of a γ-phosphate from the adenosine
5’ triphosphate (ATP) to an acceptor peptide (Figure 3A) (Dekker, 2004). Enzymes that catalyze
this reaction are termed kinases, and in proteins the amino acids serine, threonine and tyrosine
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are the phosphate acceptors (Figure 3) (Hanks et al., 1988; Dekker, 2004). Research on PKC
began in the 1970’s when Nishuzuka and co-workers started to describe the cyclic nucleotideindependent kinase, today known as PKC (Inoue et al., 1977; Kishimoto et al., 1977; Takai et
al., 1977). PKC phosphorylates serine/threonine residues and differs from other kinases by the
presence of a regulatory amino terminal end.

A

B

C

D

Figure 3. Phosphorylated amino acid residues. The chemical structures
for a phosphate group (A), phosphorylated threonine (B), serine (C) and
tyrosine (D) residues are shown.

In addition, PKC also contains a catalytic domain located at the carboxyl terminal end
with highly conserved substrate- and ATP-binding sites. Traditionally, PKCs have been
classified into three groups (Nishizuka, 1988; Nishizuka, 1992; Hug and Sarre, 1993; Liu and
Heckman, 1998; Newton, 2001). The bases for this classification is found in the PKC’s Nterminal domain that is responsible for regulating kinase activity (Figure 4) (Newton, 2001). The
N-terminal domain is responsible for co-factor binding such as phosphatidylserine (PS), 1,2diacylglycerol (DAG), and Ca2+. The first group, the conventional PKCs that includes the α, βΙ,
βΙΙ, and γ isoenzymes requires DAG/PMA, PS and Ca2+ to be fully active and they were the first
to be identified from cDNA brain libraries (Figure 2). Conventional PKCs contain a C1A subdomain which is responsible for the allosteric binding to PS, a C1B sub-domain responsible for
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PMA/DAG allosteric binding, and a C2 sub-domain with 4 aspartate residues that form a pocket
for Ca2+ binding. The second group, the novel PKCs, includes isoenzymes ε, δ, θ, η/L, and they
have the same sub-domains found in the conventional group but the C2 sub-domain lacks the
aspartate residues responsible for Ca2+ binding. The third group, the atypical PKCs includes the
isoenzymes ζ, ι/λ. In this group, the C1 sub-domain is the only one remaining from the previous
three sub-domains at the amino terminal, and can only be activated by PS and
phosphatidylinositides (Liu and Heckman, 1998; Newton, 2001).

Figure 4. Diagram of the protein kinase C family. The amino-regulatory and the carboxyl-catalytic
domains are shown for each one of the PKC groups (blue bar). The binding sites for PS and
DAG/PMA are shown in orange, and the Ca2+-binding site in yellow.. This diagram was adapted from
Newton, 2001.

Complete activation of PKC depends on three steps: phosphorylation, allosteric binding
of signal lipids and/or Ca2+, and translocation from the cytoplasm to the cell membrane (Newton,
2001). All of these interactions together result in kinase activation and phosphorylation of target
proteins. Interestingly, inactivation of PKC is linked to its own degradation via the ubiquitinproteasome pathway (Lu et al., 1998). Hence PKCs play important roles in several signal
transduction pathways that regulate a variety of functions involving receptor desensitization,
activation or inactivation of ion channels and transporters. During the last two decades, it has
been demonstrated that PKC strongly regulates the activity of many neurotransmitter
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transporters, including the SLC6 transporter. Several changes have been described in transporters
after activation of PKC by the drug PMA including phosphorylation, ubiquitination and
downregulation of several SLC6 transporters. Although the general role of PKC on regulation of
transporter activity is well established, the PKC isoenzyme(s) involved in the regulation of the
GlyT1 or phosphorylation is not known.

1.3 Dissertation aims
The GlyT1 shares sequence and structural similarities with other transporters, mainly
with the dopamine and serotonin transporters, which are known to be phosphorylated (Granas et
al., 2003). The group of Sato et al. (1995) described that glycine uptake mediated by GlyT1b is
decreased after PMA treatment in HEK-293 cells stably expressing the GlyT1. Moreover, they
mentioned that several phosphorylation sites are present along the GlyT1 sequence, and since
then it has been assumed that GlyT1 is phosphorylated without the corresponding experimental
evidence. Therefore, our goals in this dissertation are:

Aim 1. To determine the phosphorylation of the GlyT1, and the PKC isozyme involved in
triggering GlyT1 posttranslational modifications, using a variety of biochemical techniques.
Specifically, we will investigate i) whether GlyT1 is phosphorylated in a PKC-dependent fashion
and ii) elucidate which PKC isozyme(s) is/are involved in GlyT1 phosphorylation using a
pharmacological approach.

Aim 2. To map a phosphorylation domain or sites along the GlyT1 sequence. The identification
of phosphorylation sites will be performed by site-directed mutagenesis. By stably expressing the
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GlyT1 mutants, we will be studying i) phosphorylation in response to PMA by metabolic
labeling assay and ii) the effect of PKC on glycine uptake mediated by the mutants and wild-type
control.

Aim 3. To determine the possible localization of the substrate-pocket in a three-dimensional
model of the GlyT1. To date, crystallographic information of neurotransmitter transporters is not
available and the only information about the mechanism of substrate recognition and transport
pathway has been obtained by structure-function relationships studies. To gain information about
the structure, we built a homology model of the GlyT1b based on the crystal structure of the
leucine transporter (LeuT; PDB code 2A65) from the bacteria Aquifex aeolicus (Yamashita et al.,
2005). Therefore, our goal will be to map the amino acid residues that may participate in the
formation of the substrate-pocket by cysteine scanning chemical labeling, using fluorescently
labeled-maleimides (sulfhydryl alkylants).
The goals, objectives and accomplishments of each specific aim will be detailed in the
following chapters.
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Chapter 2: Phosphorylation and regulation of the Glycine Transporter 1 by
conventional protein kinase C isoenzymes
It has been shown that the specific activation of PKC leads to a downregulation of the
GlyT1 activity, either in stably expressing cells or endogenous GlyT1 (Sato et al., 1995; Gomeza
et al., 1995). However, there are around 10 PKC isoenzymes described and it is not known
which one is involved in the regulation of the GlyT1. As previously demonstrated, kinetic
analysis for some SLC6 members had established that PKC activation downregulates the Vmax of
the transporters, but it does not modify the affinity for the specific substrate (Huff et al., 1997).
Given the lack of information about the PKC isoenzyme involved on GlyT1 regulation and its
role in phosphorylation, our goal is to determine the phosphorylation of the GlyT1 and the PKC
isoenzyme involved in the regulation of the GlyT1. With this background information, we
proceeded to analyze the amino acid sequence of the GlyT1 and identify potential
phosphorylation motif(s). Then we studied the phosphorylation of the GlyT1 followed by
identification of the PKC isoenzymes involved in regulation of GlyT1.
Aim 1. To determine the phosphorylation of the GlyT1, and the PKC isozyme involved in
triggering GlyT1 posttranslational modifications, using a variety of biochemical techniques.
Specifically, we will investigate i) whether GlyT1 is phosphorylated in a PKC-dependent fashion
and ii) to elucidate which PKC isozyme(s) is/are involved in GlyT1 phosphorylation using a
variety of specific inhibitors to different PKC isoenzymes.

2.1

MATERIALS AND METHODS

2.1.1 Chemicals and antibodies
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The radioactive [3H]-glycine and [32P]-orthophosphate were purchased from Perkin
Elmer Life Scientific (Boston, MA). Antibody to α-actin, Flag-M2 agarose beads, PMA, Nethylmaleimide, KN-93, sodium fluoride, phosphatase inhibitor cocktail, sodium orthovanadate,
phenylmethanesulfonyl fluoride, aprotinin and leupeptine were purchased from Sigma-Aldrich
(St. Louis, MO). The PKA selective inhibitor KT5720 was kindly provided by Dr. Robert
Kirken’s laboratory (University of Texas at El Paso). BIM, HDBBE (2,2′,3,3′,4,4′-Hexahydroxy1,1′-biphenyl-6,6′-dimethanol Dimethyl Ether), rottlerin, KN-92, Gö6976, Gö6983, LY333531
and PKCβ inhibitor (3-(1-(3-Imidazol-1-ylpropyl)-1H-indol-3-yl)-4-anilino-1H-pyrrole-2,5dione) were purchased from EMD (San Diego, CA). HRP-labeled secondary antibodies were
obtained from Promega Co. (Madison, WI). Rabbit polyclonal antibodies to GlyT1 were kindly
donated by Detlev Boison and Dietmar Benke (University of Zurich). Monoclonal mouse to
PKCβΙ (Ε3) and the polyclonal PKCβΙΙ (C−16) and PKCβΙΙ (C−18) antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal mouse antibody to PKCα and
PKCβ (123-324) was purchased from Abcam Inc. (Cambridge, MA) and from BD Bioscience
(San Jose, CA) respectively. Monoclonal antibody specific to multiple phosphotyrosine (pY) was
purchased from Invitrogen (Carlsbad, CA).

2.1.2 Plasmid constructs
The cDNA encoding for the mouse GlyT1a was purchased from the American Type
Culture Collection (ATCC), and the human isoforms GlyT1b and GlyT1c were kindly donated
by Bruno Giros (INSERM, France). The three isoforms were tagged with Flag and 10X-His
epitopes at their N-termini (FH-GlyT1) as previously described (Miranda et al., 2005). The
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resulting constructs were cloned into pCDNA 3.1 and the DNA sequence was verified by
automatic deoxynucleotide sequencing.

2.1.3 Cell culture and transfections
Dr. A. Sorkin kindly provided PAE cells (University of Colorado at Denver) grown at
37oC and 5% CO2 in Ham’s F12 medium containing 10% FBS and gentamicin (100 μg/ml). PAE
cells were grown to 50–80% confluence and transfected with appropriate plasmids using
Effectene, according to the manufacturer’s recommendations (Qiagen, Hilden, Germany). PAE
cells stably expressing FH-GlyT1a, b or c were selected by growing them in the presence of
G418 (400 μg/ml). C6 glioma cell were grown in Ham’s F-12 Kaighn's modified medium
containing 1.25% FBS and 7.5% of horse serum under the same conditions described above.

2.1.4 Metabolic labeling and GlyT1 purification
Confluent PAE cells expressing FH-GlyT1a, b or c isoforms were incubated in a DMEMphosphate free media supplemented with 5% dialyzed-FBS for 6 h following the addition of
0.125 μCi of

32

P-orthophosphoric acid/well. After 2 h incubation, FH-GlyT1 phosphorylation

was stimulated by 1 μM PMA for different intervals of time (120, 60, 30 and 15 min) or
inhibited with 1 μM of BIM 30 min before addition of PMA. As a negative control, parental
cells were incubated with PMA or DMSO. After incubation, cells were washed twice with Ca2+and Mg2+-free cold phosphate-buffered saline (CMF-PBS) and lysed in a ice-cold-buffer
containing 25 mM Hepes, pH 8.0, 100 mM NaCl, 15 mM imidazole, 10% glycerol, 1% triton X100, 1% sodium deoxycholate, 10 mM N-ethymaleimide, 10 mM sodium fluoride, 1X
phosphatase inhibitor cocktail, 1 mM sodium orthovanadate, 1 mM phenylmethanesulfonyl
12

fluoride and 10 μg/ml aprotinin and 10 μg/ml leupeptine. Lysates were cleared by centrifugation
at 14,000g and soluble FH-GlyT1 was purified by a double affinity chromatography. Briefly,
cleared lysates were incubated with Ni-NTA affinity agarose beads for 1 h and eluted with
imidazole. The eluted protein was further incubated with anti-flag affinity agarose beads for 4 h
and eluted with 100 mM glycine, pH 3.5 (Miranda et al., 2005). The fractions containing FHGlyT1 were subjected to 8.0% SDS-PAGE and transferred to a nitrocellulose membrane as
previously described (Laemmli 1970; Towbin et al., 1979). Finally, the nitrocellulose
membranes containing

32

P-FH-GlyT1 were subjected to autoradiography followed by western

blot using an antibody specific to FH-GlyT1. Signal intensities were quantified by ImageJ (NIH).
2.1.5 [3H]glycine uptake mediated by the FH-GlyT1
PAE cells stably expressing the FH-GlyT1 were incubated for 30 min with specific
inhibitors

of

PKA,

PKC,

CaMKII,

novel

PKCδ,

and

conventional

PKCα/β1,

PKCβ or PKCα/γ before the addition of 1 μM PMA. After treatment, glycine uptake was
measured as previously described with some modifications (Sato et al., 1995). Briefly,
confluents cells were washed with 0.25 ml of reaction media containing: 10 mM Hepes pH 7.4,
135 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgSO4 and 10 mM glucose. Uptake was
initiated by the addition of reaction media containing 4 μCi [3H]glycine/ml and 200 μM cold
glycine for 10 min at 37oC. After incubation, cells were washed twice with ice-cold reaction
buffer, and [3H]glycine was extracted with 0.2 N of NaOH. Finally, glycine uptake was
determined by scintillation spectroscopy, and protein concentration was determined as described
by Bradford (1976). The specific glycine uptake is represented as the difference between the
total glycine uptake from FH-GlyT1 expressing cells and glycine uptake by the parental PAE
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cells transfected with pCDNA. The Vmax and Km of the FH-GlyT1 isoforms were determined by
the Michaelis–Menten equation and the analysis were performed by the computer program
Sigma Plot 11 (Systat Software Inc).

2.2 Results

2.2.1 In silico analysis of the GlyT1 sequence
GlyT1a, b or c sequences were analyzed using NetPhos 2.0 server in order to identify
putative phosphorylation sites (Blom et al., 1999). To position the predicted sites along the
GlyT1 sequence, a topological model was constructed using the HMMTOP server (Tusnády and
I. Simon, 1998; Tusnády and I. Simon, 2001). The potential GlyT1 phosphorylation sites derived
from the analysis for the three isoforms are summarized in Table II and illustrated in the
topological models of Figure 5.
Table I. Putative phosphorylation sites high-scored for GlyT1
Position

Sequence

Residue

GlyT1

102
239
600
625
19
597
598
11
12
107
244
605
636
640
24
11
12
38
161
298
659
78

VWRISPMFK
GVKSSGKVV
TTTPSPEDG
GSNGSSRFQ
PSEATKKDQ
YAPTTTPSP
APTTTPSPE
PVAPSSPEQ
VAPSSPEQN
VWRISPMFK
GVKSSGKVV
TIAPSPEDG
RLQDSRIHS
SRIHSCQGS
PSEATKRDQ
PVAPSSPEQ
VAPSSPEQV
TPSTSLAES
VWRISPMFK
GVKSSGKVV
TIAPSPEDG
PSEATKRDQ

S
S
S
S
T
T
T
S
S
S
S
S
S
S
T
S
S
S
S
S
S
T

a
a
a
a
a
a
a
b
b
b
b
b
b
b
b
c
c
c
c
c
c
c
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Interestingly, all three GlyT1 isoforms (a, b and c) showed 7-8-7 high-scored sites
respectively, and 5-6-5 of those sites were found in both N- and C-terminal tails, that account for
70% of all the predicted high-scored sites.

GlyT1a

These predictions strongly support
the hypothesis that phosphorylation may
be occurring at the GlyT1s N- and Cterminal tails. In addition to these
findings, GlyT1a and b have almost all
GlyT1b

the phosphorylation sites at the Cterminus and only 1 at the N-terminus,
suggesting that the C-terminal tail of
these transporters is mostly responsible
for phosphorylation. By contrast, GlyT1c
showed an equal distribution of putative

GlyT1c

phosphorylation sites at both ends. It is
worth mentioning from the previous
analysis that the consensus sequences
VWRIsPMFK and GVKSsGKVV are
conserved among the three isoforms
(Table II).

Figure 5. Putative topologies of GlyT1 isoforms. The 12
transmembrane domains are highlighted in yellow and Nglycans in blue colors. The distribution of putative
phosphorylation sites are shown in large circles, blue
(serine) and green (threonine).
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Table II. Putative phosphorylation sites conserved among GlyT1 isoforms
Sequence blasted
VWRIsPMFK
VWRIsPMFK
VWRIsPMFK
GVKSsGKVV
GVKSsGKVV
GVKSsGKVV

Position

GlyT1

102
107
161
239
244
298

a
b
c
a
b
c

In addition, three consensus sequences were only conserved among the GlyT1b and
GlyT1c, suggesting a closer relationship between these transporters (Table III).
Table III. Putative phosphorylation sites conserved among GlyT1a and b
isoforms
Sequence blasted

Position

GlyT1

PVAPsSPEQ
PVAPsSPEQ
TIAPsPEDG
TIAPsPEDG
PSEAtKRDQ
PSEAtKRDQ

11
11
605
659
24
78

b
c
b
c
b
c

The GlyT1 sequences were also analyzed by NetPhosK 1.0 server to predict the protein
kinase(s) that may be involved in the phosphorylation of the GlyT1. As illustrated in Table IV,
phosphorylation sites for a large number of kinases were found, including sites for PKA, PKC
and PKG.
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Table IV. Kinases predicted to be involved in GlyT1 phosphorylation

Sequence residue

Kinase

GlyT1

T-19
S-92
S-92
S-239
S-239
S-323
T-575
S-578
S-578
S-578
T-596
T-597
T-598
S-600
S-11
S-11
S-12
S-12
T-24
S-97
S-97
S-244
S-244
S-328
T-580
S-583
S-583
S-583
T-601
S-605
S-605
S-11
S-12
S-12
S-31
T-34
T-34
S-42
S-64
T-78
S-151
S-151
S-298
S-298
S-370
S-382
T-634
S-637
S-637
S-637
T-655
S-659
S-659

PKC
DNAPK
ATM
PKC
PKG
PKA
PKC
PKA
PKG
cdc2
PKC
PKC
cdk5
CKI
CKII
cdc2
p38MAPK
cdk5
PKC
DNAPK
ATM
PKC
PKG
PKA
PKC
PKA
PKG
cdc2
PKC
CKI
GSK3
cdc2
p38MAPK
cdk5
cdc2
p38MAPK
cdk5
PKC
DNAPK
PKC
DNAPK
ATM
PKC
PKG
PKC
PKA
PKC
PKA
PKG
cdc2
PKC
CKI
GSK3

a
a
a
a
a
a
a
a
a
a
a
a
a
a
b
b
b
b
b
b
b
b
b
b
b
b
b
b
b
b
b
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c
c
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The analysis revealed that PKC-dependent phosphorylation sites are more abundant when
compared to sites for other kinases, as plotted in Figure 6.

GlyT1a

GlyTs

PKC
35.71%

DNAPK
3.92%

PKC
29.41%

ATM
5.88%

DNAPK
7.14%

PKG
11.76%

ATM
7.14%

GSK3
3.92%
PKA
11.76%

cdc2
11.76%

cdk5
7.84%

p38MAPK
5.88%
CKII
1.96%
CKI
5.88%

CKI
7.14%

PKG
14.28%

cdk5
7.14%

GlyT1b
ATM
5.88%

cdc2
7.14%

PKA
14.78%

GlyT1c

DNAPK
5.88%
PKC
23.52%

PKG
11.76%

ATM
5.88%

DNAPK
3.92%

PKC
29.41%

PKG
11.76%

PKA
11.76%

GSK3
5.88%

PKA
11.76%
GSK3
3.92%

p38MAPK
5.88%
cdc2
11.76%
cdk5
5.88%

CKI
5.88%

cdc2
11.76%

CKII
5.88%

cdk5
7.84%

CKI
5.88%

p38MAPK
5.88%

Figure 6. Predicted protein kinases involved in the phosphorylation of the GlyT1 isoforms. Pie
charts indicating the percentage of phosphorylation sites for a selective kinase. Predictions for GlyT1
isoforms together or for each one of the GlyT1 isoform a, b or c are shown.
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Taking all these findings together, we concluded that GlyT1 isoforms are potential targets
for phosphorylation, and it is likely that PKC may be playing a critical role in transporter
phosphorylation.

2.2.2 Activation of protein kinase C decreases glycine uptake and enhances GlyT1
phosphorylation
In agreement with published work, our preliminary data shows that specific uptake
mediated by neurotransmitter transporters is reduced after PKC activation, and this reduction is
accompanied by transporter endocytosis into endosomes (Sorkina et al., 2003). To analyze the
effect of PKC activation on GlyT1 activity, glycine uptake was measured in PAE cells stably
expressing the GlyT1a, b or c isoforms tagged with Flag and His at the N-terminus (FH-GlyT1).
FH-GlyT1 immunostaining and fluorescence microscopy showed that FH-GlyT1 isoforms
trafficked through the biosynthetic pathway and were delivered to the plasma membrane. As
shown in Table V and Figure 7, incubation of PAE/FH-GlyT1 cells with DMSO resulted in Vmax
(37-41 nmol/min/mg) and Km (112-176 μM) values that were similar to those described for nontagged transporter (Kim et al., 1994; Olivares et al., 1994). In agreement with the previous
findings obtained from expressing GlyTs in different model cell types, cells incubated with PMA
led to a reduction in the Vmax (23-31 nmol/min/mg), without any significant change in Km values
(Table V and Figure 7). These results showed that FH-GlyTs are fully functional in PAE cells
and that the response to PMA is similar to the other previously described expression systems.
Another PKC-mediated event described for DAT, SERT and NET is phosphorylation
(Foster et al., 2000; Granas et al., 2003). As previously described, the GlyT1 sequence contains
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GlyT1b

GlyT1a

Table V. Kinetic properties of GlyT1 isoforms

GlyT1c

Figure 7. Effect of PMA in glycine uptake. PAE cells stably expressing GlyT1a, b or c isoforms were
incubated with DMSO (o) or 1 μM PMA (●) for 1 h, followed by glycine uptake. The assay was performed in
the presence of increasing concentrations of cold glycine 10-400 μM and 4 μCi/ml of [3H]glycine at 37oC.
Kinetic parameters were calculated using the Michaelis-Menten equation and Sigma Plot 10. Values represent
the mean at of least 3 determinations ± standard error. * , p=0.005, **, p=0.008, ***p=0.022 compared to the
cells treated with vehicle (DMSO).

multiple canonical serine/threonine phosphorylation sites for PKC and other kinases, all located
in cytosolic regions of the protein. Although it has been suggested that GlyT1b is phosphorylated
in response to PKC activation. However, there is not experimental evidence to suggest that this
post-translational modification takes place in any of the GlyT1 isoforms (Sato et al., 1995). To
determine whether GlyT1 isoforms were indeed phosphorylated, we performed metabolic
labeling assay of the FH-GlyT1/PAE cells with [32P]-orthophosphate, and then the cells were
stimulated with PMA over different periods of time (0-120 min) followed by purification of the
20

FH-GlyT1 by double affinity chromatography. The purified transporter was subjected to SDSPAGE and autoradiography. As shown in Figure 8, when the transporter was purified from nonstimulated cells a faint, sometimes undetectable, radiolabeled band of 75 kDa was observed,
consistent with the corresponding molecular weight for FH-GlyT1.

Figure 8. Activation of PKC triggers phosphorylation of GlyT1 transporter.
PAE cells expressing GlyT1a, b or c isoforms (pannels A, B and C respectively)
were labeled with 0.125 μCi 32P-orthophosphate/well as described in
“experimental procedures” followed by incubation with 1 μM PMA for 0-120 min,
or 1 μM BIM followed by the addition of 1 μM PMA. Labeled GlyT1 was purified
by tandem affinity chromatography and analyzed by autoradiography and western
blotting with GlyT1 antibodies. The right pannel shows the quatification of
phosphorylated GlyT1 normalized by the total GlyT1 (mean+/- SE, n=2-3). As
control experiments, purification from parental cells is presented.

By contrast, treatment of the cells with 1 μM PMA induces a time-dependent increase in
FH-GlyT1 phosphorylation, with more than ~2-3 fold increase in the phosphorylation signal
after 15 min and reaching a maximum level at 30-60 min of incubation with PMA. Interestingly,
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intensity measurement of the phosphorylated band normalized by the total transporter followed a
bell shape-curve suggesting that transporter phosphorylation is transient, and peaks at 30-60 min
followed by dephosphorylation. Similar patterns of phosphorylation were obtained for FH-GlyT1
isoforms b and c (Figure 8, panels B and C). The 75 kDa band was absent from the precipitates
obtained from parental PAE cells that were labeled with 32P and no immunoreactive band with
GlyT1 antibodies was detected.
Although serine/threonine phosphorylation is well documented for DAT, SERT and NET,
whether tyrosine or serine/threonine residues are responsible for GlyT1 phosphorylation remains
unexplored. The human FH-GlyT1a sequence contains several tyrosine residues located in the
cytoplasmic side, one tyrosine in the third (Y320) and fifth (Y483) intracellular loop and one in
the C terminus (Y593). The distribution of these tyrosine residues in GlyT1s is well conserved
among GlyT1a, b and c isoforms. The only discrepancy is shown for GlyT1c, with an extratyrosine residue in the amino-terminus. To rule out the potential contribution of tyrosine residues
on GlyT1 phosphorylation, we incubated FH-GlyT1a, b or c/PAE cells with PMA for 60 min,
further purified under the same condition used in the metabolic labeling experiments and
subjected to western blotting with a specific anti-phosphorylated tyrosine antibody (pY). As
controls, we used the epidermal growth factor (EGF) receptor, a receptor known to be
phosphorylated at tyrosine residues, which was immunoprecipitated from cells stimulated with or
without EGF for 2 min. As shown in Figure 9A, blotting with the specific anti-phosphotyrosine
antibody readily detected the EGF-induced tyrosine phosphorylated receptor whereas no signal
was detected in the lanes corresponding to FH-GlyT1a, b or c. The blot was further incubated
with EGF receptor and GlyT1 antibodies, which resulted in the appearance of bands
corresponding to the receptor and transporter with their expected molecular weight (Figures 9,
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panels B and C). Essentially, these results suggest that similar to other members of the SLC6
family, serine/threonine residues found in GlyT1 are also PKC-dependent phosphorylation sites.
However, we do not know whether PKC is directly interacting with GlyT1 or activating a
pathway that targets phosphorylation of GlyT1. These are the questions that still remain to be
answered.

Figure 9. Immunodetection of tyrosine phosphorylation
for EGF receptor and GlyT1. FH-GlyT1a, b or c/PAE cells
were incubated with DMSO or PMA for 1 h following
purification of the transporter. In control samples, HeLa cells
were incubated with 20 ng/ml of EGF for 2 min followed by
immunoprecipiation of EGF receptor. Purified transporter
and immunoprecipitates were subjected to western blotting
with anti-phosphotyrosine (pY), EGFR and GlyT1
antibodies. A representative blot of three different
experiments is shown.
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2.2.3 Inhibition of conventional PKCα/β abolished the PKC-dependent reduction in [3H]glycine
uptake.

A number of studies have reported that classical PKCβ isoenzyme physically associates
with DAT and regulates trafficking and amphetamine-stimulated outward dopamine transport
through the dopamine transporter (Doolen et al., 2002; Johnson et al., 2005; Chen et al, 2009).
Moreover, it has been suggested that PKCα isoenzyme regulates the PMA-reduced uptake of
glycine in C6 glioma cells (Morioka et al., 2008). To get further insights into the mechanism of
regulation of glycine uptake and GlyT1 phosphorylation in FH-GlyT1/PAE cells, we performed
an extensive pharmacological study by using a variety of kinase inhibitors and assayed the effect
on glycine uptake. In agreement with previous studies on DAT (Daniel et al., 1999), an
incubation of FH-GlyT1b/PAE cells with the PKA (KT5720) or CaMKII (KN93) inhibitors did
not prevent the PMA-induced reduction in glycine uptake that could be abolished by the specific
PKC inhibitor BIM, demonstrating that PKA and CaMKII do not participate in the

Figure 10. Effect of kinase inhibitors on the PMA-dependent reduction of glycine uptake.
FH-GlyT1b/PAE cells were incubated for 30 min at 37oC with either of the following
inhibitors, before treatment with 1 μM PMA, (A) 5 μM KT5720 (PKA inhibitor) or 15 μM
KN92 or KN93 (non-active and active CaMKII inhibitor respectively), (B) rottlerin (novel
PKCδ inhibitor), (C) Gö6983 (inhibitor of conventional PKCs). After PMA treatment for 1 h,
glycine uptake was measured as described in “experimental procedures”. Data bars represent
the mean ± SE, n=4-8, *, + , p=<0.001, ++, p=0.048, ‡, p=0.001, *, p=0.008 compared to
cells treated with vehicle (DMSO).
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downregulation of glycine uptake (Figure 10).
As was expected, our positive control BIM, by itself, did not affected the glycine uptake
of GlyT1 (Figure 11F). Given that PMA activates novel and conventional PKCs, we then
examined the effect of different concentrations of rottlerin, an inhibitor of the novel PKCδ, on
glycine uptake. As shown in Figure 10B, preincubation of FH-GlyT1/PAE cells at
concentrations below and above the IC50 (3 nM) did not affect the downregulation induced by
PMA. Moreover, to determine the role of conventional PKCs on GlyT1 activity, we incubated
FH-GlyT1b/PAE cells with increasing concentrations of the selective PKCα, β, γ and δ inhibitor
Gö6983. As expected, preincubation of the cells with increasing concentrations above the IC50
(7 nM) gradually prevented the PMA-induced reduction in uptake to levels similar to those found
in vehicle or BIM/PMA treated cells (Figure 10C). Similar findings were obtained with Gö6976,
a more selective inhibitor of classical PKCα/β. As shown in Figure 11A, incubation of FHGlyT1b/PAE cells with 3 nM Gö6976, a concentration below the IC50 value (~6 nM) did not
prevent the effect of PMA; by contrast, a concentration of 10 nM or above was sufficient to
completely abolish the PMA-induced reduction in glycine uptake. These results together suggest
that conventional PKCα and/or β are responsible for the downregulation of glycine transport.
We further analyzed the effect of more specific inhibitors to PKCα and PKCβ on the GlyT1
activity. As shown in Figure 11, panels B, C, D and E, incubation of the cells with varying
concentrations of the PKCβ or PKCα inhibitors or mixtures did not prevent the reduction of
glycine transport triggered by PMA, suggesting that PKCα or PKCβ or together regulates GlyT1
activity. Although the pharmacological analysis provided information about the PKC isoenzyme
responsible for the regulation of GlyT1 activity, it does not show the presence and the amount of
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PKC contained within the cell. To determine whether PKCα and PKCβ were expressed in PAE
cells, control tissue lysates from
cerebellum or brain (Wetsel et al.,
1992) or different amounts of FHGlyT1b/PAE cell lysates were
subjected

to

immunoblotting

SDS-PAGE
with

and

specific

antibodies to PKCα, PKCβΙ or
PKCβΙΙ, obtained from different
suppliers. As shown in Figure 12A
and 12B blotting with the antiPKCα

and

PKCβ antibodies

respectively, readily identified an
immunoreactive ~75 kDa band
corresponding to PKCα and PKCβ
from cerebellum, brain and PAE
cells,

in

agreement

with

the

predicted size of the polypeptide.
Given that PKCα and PKCβ
migrated with similar molecular
weight in SDS-PAGE, the identity
of

each

isozyme

was

further

Figure 11. Effect of specific PKCα and/or PKCβ inhibitors on
GlyT1 activity. FH-GlyT1b/PAE cells were incubated with the
following specific inhibitors of conventional PKCs for 30 min at
37 oC before treatment with PMA for 1 h, (A) Gö6976 (PKCα/β
inhibitor), (B) HBDDE (PKCα/γ inhibitor), (C) PKCβ inhibitor,
(D) LY333532 (PKCβ inhibitor) or a mixture (E). Effect of
different concentrations of BIM in glycine uptake, p=116 and n=6
did not show a sinificant effect in glycine uptake (F). After
treatment, glycine uptake was meassured as described in
“experimental procedures”. Data bars represent the mean ± SE,
n=4-8. , p=<0.001, ++, p=0.048, ‡, p=0.001, *, p=0.008, **,
p=0.006, ***, p=0.002 compared to cells treated with vehicle
(DMSO).

corroborated by performing a two-dimensional gel electrophoresis followed by western blotting
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with the corresponding antibodies. Consistent with the previous results, PKCα and PKCβ1 were
detected at the same molecular weight but, separated by their differences in iso-electric values
(Figure 12C). These findings confirmed the expression of both isozymes in PAE cells. A recent
study by Morioka et al. (2008) reported that GlyT1 activity is regulated by PKCα and their
conclusion was based on the observation that the anti-PKCβ antibodies used in their study did
not detect PKCβ in C6 glioma cells. Their results raised an important issue that needed further
investigation. To address this confusion, we decided to test the ability of different antibodies to
recognize the PKC isozymes. Different quantities of total lysate from C6 glioma cells were
subjected to western blotting with anti-PKC antibodies from different sources. As mentioned
above, PKCα was detected in control and PAE cell lysates with the anti-PKCα antibody
(ABCAM), consistent with earlier observations in C6 glioma cells from Morioka et al. (2008).

By contrast, blotting with a monoclonal (E3) or polyclonal (C-16) anti-PKCβ1 antibodies
readily detected a ~75 kDa band in controls and C6 glioma cells corresponding to PKCβΙ,
suggesting expression of this isozyme and to similar levels in both C6 and PAE cells. In addition,
using specific polyclonal anti-PKCβII antibodies (C-18), we were able to detect expression of
PKCβII in C6 glioma cells and to a lower level in PAE cells, indicating the presence of both
PKCβ isozymes (Figure 12B). However, to clarify some of the confusion related to the
expression of PKCβ in C6 glioma cells, we tested additional lysate samples with the antiPKCβ antibody used by Morioka et al. (2008). As illustrated in the bottom panel of Figure 12B,
PKCβ was detected by the anti-PKCβ (123-324) antibody at the predicted molecular weight in
both PAE and C6 glioma cells. These results together with the pharmacological studies
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confirmed the expression of the conventional PKCα as well as PKCβΙ in PAE and C6 glioma
cells.

Figure 12. Immunodetection of PKCα and PKCβ isoenzymes in PAE and C6 glioma cells. PAE
or C6 glioma cells were lysed and different quantities of lysates were subjected to western blotting
with different PKCα and β antibodies. Blotting with actin antibodies was used as loading control. As
a positive control, 50 μg of freshly prepared of rat brain or cerebellum homogenate was used. Total
protein concentration was determinate by the Bradford assay.

2.2.4 PKCβ is responsible to trigger GlyT1 phosphorylation in PAE cells

We have determined that PKCα and PKCβ are responsible for the changes in glycine
uptake; however, it is not known whether a sole PKC isozyme is responsible for the changes in
transporter phosphorylation. To determine whether it is PKCα or β isoenzyme that is involved in
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the enhanced GlyT1 phosphorylation, we performed metabolic labeling of FH-GlyT1/PAE cells
and the role of different PKC inhibitors was assayed. As shown in Figure 13, when GlyT1 was
purified from vehicle treated cells, low levels of phosphorylated transporter were detected
suggesting that some GlyT1 molecules in the population are phosphorylated at steady state.
In agreement with the previous results, when GlyT1 was purified from cells exposed to
PMA for 1 h, phosphorylation was dramatically increased (up to ~2-3 folds). The PKC
dependency

was

confirmed

by

pretreatment of the cells for 30 min
with 1 μM BIM which abolished the
increase in GlyT1 phosphorylation
(Figure 13, lane 3). We previously
showed that the inhibitor Gö6976 of
conventional

PKCs

prevented

the

PMA-dependent decrease in glycine
uptake. Therefore, we preincubated the
FH-GlyT1b/PAE cells with 1 μM
Gö6976 for 30 min followed by the
addition of 1 μM PMA for 1 h. Not

Figure 13. Enhanced GlyT1 phosphorylation is dependent
on PKCβ activation. FH-GlyT1b/PAE cells were grown to
80-90% confluency and labeled with 0.125 μCi 32Porthophosphate/well for 2 h. After labeling, cells were
incubated for 30 min in the presence of the following
selective PKC inhibitors: Gö6976 (PKCα/β ), PKCβ inhibitor
or
LY333531
(PKCβ
inhibitors)
or
HDBBE
(PKCα/γ inhibitor) before addition of 1 μM PMA for 1 h.
After labeling, GlyT1 was purified by affinity double
chromatography and analyzed by autoradiography and
western blotting with GlyT1 antibodies. A representative of 5
different experiments is shown in this figure.

surprisingly, the inhibitor blocked the PKC-dependent GlyT1 phosphorylation (Figure 13, lane
4). Furthermore, 30 min pre-treatment of the cells with either of the two selective
PKCβ inhibitors (referred as: PKCβ inhibitor and LY333531) prevented the activation of PKC
by PMA and abolished the increased on GlyT1 phosphorylation (Figure 13, lanes 5 and 6). By
contrast, enhanced GlyT1 phosphorylation was observed after incubation with 50 μM of the
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specific PKCα/γ inhibitor HDBBE and further stimulation with PMA (Figure 13, lane 7). All of
these findings together demonstrate that PKCα/β are responsible for the PMA-induced inhibition
of glycine uptake whereas PKCβ regulates the increase in GlyT1 phosphorylation (Figure 14).
Whether phosphorylation is implicated in controlling the downregulation of glycine transport is a
question that remains to be studied.

2.3 Discussion
A meticulous analysis of the GlyT1 sequences revealed the high influence that PKC may
have on several aspects of GlyT1 function. In silico analysis showed that GlyT1 isoforms contain
multiple putative sites for phosphorylation and most of the sites were found to be consensuses
for PKC; however, how much of this prediction is valid is a question that remains be answered.
Activation of PKC by PMA has been a traditional approach for studying pathways that involve
PKC (Sato et al., 1995; Huff et al., 1997; Vaughan et al., 1997; Qian et al., 1997; Doolen and
Zahniser, 2002; Tanaka et al., 2004; Jayanthi et al., 2005). PMA is an analogue compound of
DAG which has several advantages (Newton, 2001). One of the most important advantages is
that it is not degraded by the cell, as it happens for DAG. According to our data, activation of
PKC simultaneously produced a downregulation in GlyT1 activity and enhanced
phosphorylation of the transporter. Similar results have been obtained for other member of the
SLC6 family of neurotransmitters (Huff et al., 1997; Foster et al., 2000; Granas et al., 2003).
However, PKC is not the only kinase activated by PMA; indeed it has been reported that MAPK
can be activated by this drug; however, the selective PKC inhibitor BIM inhibited the
downregulation and phosphorylation of GlyT1 mediated by PKC which fully establishes the role
of PKC in regulating GlyT1 activity.
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The enzymatic transfer of a phosphate group from ATP to a protein usually targets a
tyrosine or threonine/serine residue(s), depending on the kinase(s) type involved in a
phosphorylation process (Dekker, 2004). Importantly, we determined that GlyT1a, b and c were
PKC- and time-dependent phosphorylated, but not the specific domains and residues that were
being phosphorylated. In order to determine if tyrosine(s) residue(s) was/were the target during
GlyT1 phosphorylation, we performed a western blot using antibodies to detect phosphorylated
tyrosine residues. Surprisingly, phosphorylation of tyrosine residues was not detected in GlyT1
from cells stimulated with PMA or without the stimulation, which suggested that the phosphate
acceptor may be a threonine or/and serine residue(s). Nevertheless, phosphorylation of tyrosine
residues have not been described for any of the SLC6 members. An in silico analysis of the
GlyT2 sequence showed that tyrosine residues 591 in the 4th cytoplasmic loop and 764 in the
COO-terminus were high-scored and they could be phosphorylated; however phosphorylation of
the GlyT2 is still not reported.
The relationship between PKC and GlyT1 could be very complicated, because the PKC
family is a variable family of more than 10 members grouped into 3 groups (Newton, 2001).
However, the availability of selective inhibitors for different PKC isoenzymes seems to have
higher specificity. Although there are no inhibitors for each one of the PKC isoenzymes, there
are a large number of inhibitors available that may be helpful for the analysis of pathways that
involve PKCs (Kase et al., 1987; Toullec et al., 1991; Gschwendt et al., 1994; Sumi et al., 1991;
Gschwendt et al., 1996; Martiny-Baron et al., 1993; Tanaka et al., 2004).
Pharmacological analysis of the downregulation of the activity and phosphorylation of
GlyT1 was analyzed using selective inhibitors for PKA, CaMKII, novel and conventional PKCs.
Initial results suggested that glycine uptake was downregulated by activation of PKC; however,
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only the PKCα/β selective inhibitor (Gö6976) was able to inhibit the downregulation in GlyT1
activity. In contrast, the selective inhibitors to PKCβ (PKCβ and LY333531 inhibitors
respectively), and to PKCα/γ (HDBBE), or a mixture of both failed to prevent the
downregulation in glycine uptake. In addition, LY333531 has been referred as an excellent
inhibitor and widely cited in the literature. This is not the case for HBDDE, which exhibited a
high IC50 (~50 μM) compared to the PKCβ and Gö6976 inhibitors that exhibited IC50s around
20 nM. Unfortunately, the selective PKCα inhibitor HBDDE was the only one commercially
available to validate our data. Given that Gö6976 was the only inhibitor that prevented the effect
of PMA, we concluded that downregulation of GlyT1 activity is mediated by PKCα and
PKCβ isoenzymes (Figure 14).
Selective inhibitors to PKCα/β and PKCβ successfully inhibited the PKC-dependent
phosphorylation of GlyT1, which strongly demonstrates that PKCβ is involved in the
phosphorylation of the GlyT1 (Figure 14). However, the HBDDE did not prevent PKCβdependent phosphorylation of GlyT1.
Recently, Morioka et al. (2008) suggested that downregulation of endogenously
expressed GlyT1 in C6 glioma cells was regulated by PKCα using selective inhibitors and
siRNA to PKCs. However, these findings were based on experiments showing that C6 glioma
cells did not express PKCβ. Similarly, we analyzed our expression system (PAE cells) in order
to confirm the expression of PKCα and PKCβ isoenzymes. An exhaustive study by western blot
using antibodies from different suppliers completely demonstrated that PKCα and the splicing
variants PKCβI and PKCβII were expressed in our cell model (PAE) and C6 glioma cell. These
findings validated the use of inhibitors and the pharmacological analysis to identify the
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contributions of PKCs (α and β) on activity and posttranslational modifications of GlyT1. Future
investigations in this area should be focused on the role of PKCα over the GlyT1 and whether
PKCβ directly phosphorylates the GlyT1.

Figure 14. Diagram indicating how the GlyT1 is regulated by the conventional PKCs. Activation of
PKCβ isoenzyme triggers the phosphorylation of the GlyT1, however activation PKCα and β isoenzymes is
required for the downregulation of the GlyT1 activity.
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Chapter 3: Phosphorylation map of the glycine transporter 1
Many examples of transporter phosphorylation occurring in the SLC6 family are
described in the literature and supported by our preliminary data (Huff et al., 1997; Vaughan et
al., 1997; Qian et al., 1997; Doolen and Zahniser, 2002; Jayanthi et al., 2005). However, the
identification of phosphorylated residues and their corresponding function(s) has been
challenging. The best example could be the phosphorylation of the N-termini of DAT, which has
been attributed as a requirement for amphetamine-induced efflux (Khoshbouei et al., 2004; Sucic
et al., 2010). As was shown in chapter 2, the GlyT1 isoforms are phosphorylated in a time- and
PKCβ−dependent fashion; however, we do not know the specific domain(s) or the
phosphorylation sites. Therefore, our goal in this chapter is to provide preliminary data about the
domain(s) being phosphorylated in GlyT1.
Aim 2. To map a phosphorylation domain or sites along the GlyT1 sequence. The identification
of phosphorylation sites will be performed by site-directed mutagenesis. By stably expressing the
GlyT1 mutants, we will be studying i) phosphorylation of the mutants in response to PMA by
metabolic labeling assay and ii) the effect of PKC on glycine uptake mediated by the mutants
and wild-type positive control.

3.1

MATERIALS AND METHODS

3.1.1 Reagents, enzymes and kits
Ethidium bromide was obtained from Sigma-Aldrich (San Louis, MO). Pfu turbo DNA
polymerase, XL10-gold ultracompetent cells were purchased from Agilent Technologies, Inc
(Santa Clara, CA). Primers for the PCR reactions were designed and synthesized by Eurofins
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MWG Operon (Huntsville, AL). The restriction enzyme Dpn I was obtained from New England
Biolabs (Ipswich, MA). DNA extraction kit was purchased from Promega Co. (Madison, WI).

3.1.2 Mutagenesis of serine/threonine residues
Site-directed mutagenesis was carried out using the QuikChange II Site-Directed Mutagenesis
Kit (Stratagene). Briefly, 100 ng of the appropriate primers and DNA template were added to a
typical PCR-reaction mix with final volume of 50 μl. The reaction mix was completed with the
addition of 2.5 U of Pfu turbo DNA polymerase which was placed into a thermocycler. The PCR
product was digested with 20 U of Dpn I, in order to digest all the parental DNA-template. The
reaction mix was incubated overnight at 37oC before transforming competent-bacteria DH5α
with the digested-PCR product.

3.1.3 DNA visualization
PCR products and plasmids were mixed with sample loading dye and loaded into a 1% agarose
gel-containing ethidium bromide (0.5 µg/ml) and TAE buffer (40 mM Tris acetate and 1 mM
EDTA). Finally, the gel was run for 15-20 min at 60 volts in 1X TAE buffer before DNA
visualization on a UV-transilluminator.

3.1.4 Bacteria transformation

Competent bacteria cells DH5α were used for transformation and DNA amplification. The
procedure was performed following the manufacture’s recommendations with some
modifications. Briefly, XL10-gold ultracompetent cells were thawed in ice and 25 μl of cells
were mixed in a new tube with 1 μl of the PCR’s product and β-mercaptoethanol followed by
35

incubation on ice for 30 min, before heat shock at 42oC for 30 seconds. Sample was then moved
back on ice for 2 min. After the ice-incubation, 0.9 ml of a media was added to the mix and
incubated for 1 hr at 37oC. Finally, selection of transformed cells was accomplished by growing
the bacteria in LB-ampicillin agar plates at 37oC overnight. Finally, plasmidic DNA from the
transformed cells was purified using a mini DNA extraction kit from Promega Co.

3.2 Results

3.2.1 Phosphorylation of GlyT1 mutants

The GlyT1 isoforms are phosphorylated in a time- and PKCβ-dependent manner, as
shown in the previous chapter. However, blotting with specific phosphotyrosine antibodies did
not detect any phosphorylated tyrosine residues along the GlyT1 protein, suggesting that
phosphorylation may be occurring at threonine and/or serine residue(s).
Therefore, we decided to mutate serine and threonine residues at both tails, given that
most of the putative phosphorylation sites were found in the tails, especially in the COO-termini.
Initially, we mutated all the threonine and serine residues at the amino-terminus to alanine
residues. An additional mutant contained all the threonine and serine residues mutated to alanine
residues in the carboxy-terminus. The mutants were stably expressed in PAE cells and we
conducted metabolic labeling using the wild-type GlyT1a as a positive control (Figure 15,
panels A, B and C). Phosphorylated mutants exhibited similar profiles as compared to the wildtype, as suggested by densitometry analysis (Figure 15D). As shown, mutants and wild-type did
not exhibit a relevant difference in phosphorylation levels. Clearly, these results demonstrated
that phosphorylation is occurring at both tails.
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Figure 15. Phosphorylation of the GlyT1’s N- and C-mutants. PAE cells stably expressing the
GlyT1a wild-type (A), and N- and C-mutants (B and C respectively) were subjected to metabolic
labeling assays. Phosphorylation was enhanced by 1 μM PMA for 1 hr. A quantitative plot (D) of the
phosphorylation bands adjusted by the protein intensity is shown.

3.2.2 Mutants exhibited different kinetic profiles
compared to GlyT1a wild-type
PAE cells stably expressing GlyT1a
wild-type and mutants were analyzed by
[3H]glycine uptake assay. Wild type and
mutants were analyzed in cells stimulated with
vehicle or PMA. Surprisingly, wild-type and
mutants both responded to PKC activation
exhibiting appreciable differences (Figure 16).
The N-mutant exhibited a similar Km to the
wild-type, by contrast the C-mutant showed a

Figure 16. Kinetics properties of the GlyT1
mutants. The transport properties of GlyT1a wildtype (A), and N- and C-mutants (B and C
respectively) were analyzed in stably expressing
cell lines. Cells were treated with 1 μM PMA or
vehicle (DMSO) for 1 hr before measurement of
[3H]glycine uptake. Curves were analyzed by the
Michaelis-Menten equation loaded in the computer
program Sigma plot. Bars correspond to 4 ± SE
experiments.

large reduction in the affinity for substrate (Table VI).
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Table VI. Kinetic properties of GlyT1 mutants
Transporter
FH-GlyT1a

FH-NH3-Mut

FH-COO-Mut

Treatment

Km
(μM)

Vmax
(nmol/min/mg)

DMSO

64 ± 5.6

183 ± 36.2

PMA

51.2 ± 4.2*

183 ± 32.8

DMSO

42.8 ± 4.3

191.8 ± 41

PMA

NA

NA

DMSO

9.9 ± 0.7

62.53 ± 0.1

PMA

4.7 ± 0.3**

45 ± 9

*p=0.010, **p=000.0 compared to DMSO treatment

3.3 Discussion
Experimental evidence has shown that the role of the DAT amino-terminus serves as the
main phosphorylation region of the protein (Khoshbouei et al., 2004; Sucic et al., 2010). In silico
analysis of the GlyT1 sequence presented in chapter 2 reveals how complex the phosphorylation
of the GlyT1 could be. The hypothetical phosphorylation map suggested that phosphorylation
sites could be spread along most of the cytoplasmic domains; however, the preliminary results
from this study suggest that most of the GlyT1-phosphorylation may be happening at the tails.
Therefore, we conducted a mutagenesis study in order to replace all the threonine and serine
residues at the N- and C-terminus. The rationale for taking this approach was based on previous
findings which suggest that replacement of several N-terminus serine residues does not prevent
PKC-dependent phosphorylation (Sato et al., 1995; Granas et al., 2003). These observations
suggest that phosphorylation in SLC6 transporters could be a redundant process or that several
regions of the proteins are likely to be phosphorylated. Surprisingly, mutants devoid of ser/thr
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residues at either N- or C-terminal tails were phosphorylated and densitometry analysis revealed
similar levels of phosphorylation compared to the wild-type transporter. Our findings
demonstrated that GlyT1-phosphorylation is distributed along the two tails of the GlyT1,
differing from the investigations performed in the DAT (Khoshbouei et al., 2004; Sucic et al.,
2010).
Unexpectedly, the kinetic profile exhibited by the activity of N-mutant in cells stimulated
with PMA showed a larger response compared to the wild-type transporter under the same
conditions. Unlike the N-mutant, the C-mutant exhibited a similar kinetic profile in comparison
to the wild-type transporter. Unfortunately, a study involving the double mutant (devoid of
ser/thr at both tails) is still being analyzed.
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Chapter 4: Modeling the three-dimensional structure of the Glycine
Transporter 1b
To date, crystallographic information of neurotransmitter transporters is not available,
including information about the mechanism of substrate recognition and transport pathway. In
2005 Yamasita et al. obtained the crystal structure of the bacterial leucine transporter (LeuT) at
1.9 Å. This discovery was relevant to the field because the LeuT is a homologous protein to the
SLC6 transporters. To study the structure and function relationships for GlyT1, we built a
homology model of the GlyT1b using the atomic coordinates of the solved three-dimensional
structure of the bacterial LeuT (LeuT; PDB code 2A65) and the LeuT with glycine bound to the
binding site (PDB code 3F4J) (Yamashita et al., 2005; Singh et al., 2008). With this GlyT1
model in hand, our overall goal is to find the glycine-binding site and to study structurefunction relationships by a combination of site-directed mutagenesis and chemical
modification of cysteine residues using fluorescent sulfhydryl alkylants (maleimides).
Aim 3. To determine the possible localization of the substrate-pocket in a three-dimensional
model of the GlyT1. To date, crystallographic information of neurotransmitter transporters is not
available and the only information about the mechanism of substrate recognition and transport
pathway has been obtained by structure-function relationships studies. To gain information about
the structure, we built a homology model of the GlyT1b based on the crystal structure of the
LeuT from the bacteria Aquifex aeolicus (Yamashita et al., 2005). Therefore, our goal will be to
map the amino acid residues that may participate in the formation of the substrate-pocket by
cysteine scanning chemical labeling, using fluorescently labeled-maleimides (sulfhydryl
alkylants). As an approach to test our GlyT1 models we began to study the effect of maleimides
in the activity of the GlyT1.
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4.1

MATERIALS AND METHODS

4.1.1 Chemicals and enzymes
The sulfhydryl alkylants 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin
(coumarin), N-(1-pyrenyl) maleimide (pyrenyl) and 5’-fluorecein maleimide were obtained from
Invitrogen Life Technologies (Carlsbad, CA). Others reagents were described in chapter 2.1.1.

4.1.2 In silico analysis
The initial alignment between GlyT1b and LeuT sequences was described by Yamashita
et al. (2005). We further refined the alignment and used it to build a homology model of the
GlyT1b. Re-alignments and models were accomplished by using the computer software
DeepView/Swiss-Pdb Viewer and by the structure homology-modeling server SWISS-MODEL
(Peitsch, 1995; Guex and Peitsch, 1997; Schwede et al., 2003; Arnold et al., 2006; Kiefer et al.,
2009). The resulting three-dimensional structure models were analyzed with the computer
software PyMOL (DeLano Scientific LLC). Pockets and cavities in the GlyT1b model were
analyzed and determined by CASTp server (Dundas et al., 2006).
4.1.3 [3H]glycine uptake mediated by GlyT1b
Confluent PAE cells stably expressing GlyT1b or parental cells were treated with either
fluorescein-, pyrenyl- or coumarin-maleimide for 10 min followed by three washes with 0.25 ml
of the buffer-containing: 10 mM Hepes pH 7.4, 135 mM NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM
MgSO4 and 10 mM glucose. Uptake was initiated by the addition of the same buffer-containing 4
μCi [3H]glycine/ml and 200 μM cold glycine for 10 min at 37oC. The reaction was stopped by
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removing the reaction mix and washing the cells twice with ice-cold buffer. Finally, [3H]glycine
was extracted with 0.2 N of NaOH and glycine uptake was determined by scintillation
spectroscopy.

4.2 Results

4.2.1 GlyT1b model and cavities on the model
The homology model of GlyT1b depicted in Figure 17 was based on the solved threedimensional structure of closely related bacterial
LeuT. In the final model, a large cavity facing the
extracellular side formed by the residues Y151,
C152, R153, L262, F263, G266, V267, T268,
L269, E270, F347, L350, G351, M353, A354,
N355, R363, L371, A375, Y376, E378, A379,
L380,

L382,

L382

was

identified,

likely

corresponding to the area for translocation of
2Na+/Cl-/Gly (Figure 18, panels A, C and D).
Moreover, we identified the transmembrane
domains M1 (in red) and M6 (in blue) (Figure
18B), which are part of the leucine-binding site in

Figure 17. Putative GlyT1b three-dimensional
model. Model of GlyT1b based on the crystal
structure of LeuT supports the topology of 12
transmembrane helixes.

the LeuT structure and may be involved in glycine binding (Figure 18B). The GlyT1 sequence
contains 14 cysteine residues which are spread throughout the three-dimensional structure of the
GlyT1b and were highlighted in yellow in Figure 19B. It is worth mentioning that one cysteine
residue and other amino acid forming the glycine-binding site are highlighted in the Figure 19B.
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Interestingly, of the 14 cysteine
residues, only the cysteine residue

A

B

C

D

152 was found to be part of the
substrate-pocket

where

the

glycine-binding site is located; this
residue in positioned in the large
extracellular loop of the GlyT1b
structure (Figure 19A).

Figure 18. Analysis of the GlyT1b model. Predicted cavities that
may be part of the glycine-translocation are shown in red (A).
Transmembrane domain M1 and M6, responsible for leucine
binding in LeuT, are shown in blue and red in GlyT1b model; they
may be involved with glycine binding (B). A view of the protein
surface (in green) from the cytoplasmic side (C) or extracellular
side (D) side view of the substrate-binding site in red.

A

B

Figure 19. Putative pocket-substrate and cysteine residues of
GlyT1b. Amino acid residues that may be found in the pocket-substrate
(in red) of GlytT1b are shown (A). Native cysteine residues distribution
along GlyT1 is depicted (B).
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4.2.2 Putative residues involved in glycine-binding site
The crystal structures of the LeuT showing the substrate-binding pocket with leucine,
glycine, alanine, methionine or leucine bound
were recently obtained at 1.8-2.3 Å resolution
(PDB

code

3F4J)

(Singh

et

al.,

2008).

Information from Singh’s structures was used to
model the glycine-binding site and the substratebinding pocket of the GlyT1b. According to the
GlyT1b model, residues L52, G53, Y128, Y302,
S303, A305 and T404 participate in the binding
of glycine and the two sodium ions (Figure 20).
Surprisingly, the glycine-binding site in our

Figure 20. Putative glycine-binding site for the
GlyT1b. The model seems similar that the one for
the LeuT, but residues are different. The 2 Na+ and
the substrate glycine are not shown in this model.

three-dimensional model looks very similar to the LeuT structure; most of them are hydrophilic
except the residue L52 which is conserved, being L25 in LeuT. However, LeuT glycine-binding
site has the following residues: L25 and F253, G26, S355, S256 and T254. According to the
literature, residues in the glycine-binding site should be mostly hydrophilic for them to have
solvent accessibility, this is necessary for the substrate to move from the liquid environment into
the binding site. Site-directed mutagenesis of these residues would be helpful to test the
functional role on substrate binding and occlusion. This approach will probably answer whether
these residues are part of the glycine-binding site in GlyT1b.

44

4.2.3 Effect of cysteine(s) modification on [3H]glycine uptake mediated by GlyT1b
In order to determine whether chemical modification of cysteine residue(s) was affecting
we

performed the cysteine alkylation
followed by the measurements of
glycine uptake. Interestingly, the
results showed that the hydrophobic

120

120
GlyT1b
PAE-C

GlyT1b
PAE-C

100
80
60
40

3

GlyT1,

[ H]glycine Uptake (%)

of

3

function

[ H]glycine Uptake (%)

the

20

100
80
60
40
20
0

0
0.0 0.2 0.4 0.6 0.8 1.0
N-(1-Pyrenyl)maleimide (mM)

maleimides coumarin- and pyrenyl-

0.0 0.2 0.4 0.6 0.8 1.0
7-diethylamino-3-(4'-maleimidylphenyl)4-methylcoumarin (mM)

120
GlyT1b
PAE-C

[ H]glycine Uptake (%)

maleimide rapidly inhibited glycine
uptake but not when fluorecein-5-

3

maleimide was used, a hydrophilic
molecule

that

only

modifies

cysteine residues in areas with
solvent accessibility (Figure 21).
With these results in hand, we can
speculate
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that

the

react

hydrophobic
with

cysteine
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Figure 21. Effect of maleimides on glycine uptake mediated by
GlyT1b. Uptake assay mediated by GlyT1b was measured using
200 μM glycine and 4 μCi/ml [H3]glycine. Stably transfected cells
(●) or parental cells (○) were used in order to determine the effect
of the maleimide on glycine uptake. Pyrenyl- and coumarinmaleimides were titrated from 0.002-1 mM. Fluorecein-5’maleimide was titrated from 0.05-1 mM. Experiments are the
mean ± SE of n=2 experiments. First data point represents glycine
uptake in absence of the maleimide tested. The control without
maleimide was normalizing to 100% of glycine uptake.

residue(s) lying within the glycine-binding region, preventing substrate binding or inducing a
change in conformation. On the other hand, a hydrophilic maleimide could react with more
exposed cysteine residue(s), in regions that do not participate directly in substrate binding and
translocation. Although these results are quite interesting, these questions still remain to be
answered, for example: whether these maleimides have reactivity to the same or different
cysteine residues and which is/are the reactive cysteine residue(s). Future experiments are
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needed to be conducted in order to identify which of the native cysteine residues are modified
with these fluorescent-maleimides.

4.3 Discussion
The putative topology of the GlyT1b with 12 transmembranes helixes was supported by
the bacterial three-dimensional structure of the LeuT, which was solved at a resolution of 1.9 Å
(Yamashita et al., 2005). However, LeuT has several important differences with respect to
GlyT1b, namely a very short amino- and carboxyl-terminal ends and extracellular loop. In
addition, LeuT has fewer amino acids than GlyT1b and leucine transport is not Cl--dependent, in
fact, they share around only 20-25% of sequence homology (Zafra and Giménez, 2008). More
surprisingly, LeuT can also transport and bind other amino acids such as glycine, but with low
affinity (Singh et al., 2008). More exciting was the three-dimensional structure of the glycinebinding pocket with glycine bound to LeuT, this structure opened the possibility to model the
GlyT1 with the substrate bound and identification of the residues that coordinate the substrate.
Although, cysteine residue(s) in GlyT1b was/were able to react with maleimides, identification
of these sites by LC/MS/MS in combination with site-directed cysteine mutagenesis of the
reactive cysteine is required for validation of the model, and further engineering of a freecysteine transporter. The GlyT1b lacking reactive cysteine residue(s) should be an ideal model
that can be used to map different areas in the protein such as the glycine-binding site. This
approach will allow us to introduce a new cysteine residue(s) at a desired site and test its
reactivity by chemical modification followed by glycine uptake. We would expect inhibition of
transport if a modified cysteine lies in the binding site and/or translocation pathway. Future
experiments derived from this approach should provide insights about the potential residues
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involved in substrate binding and will allow the design of more specific inhibitors to block the
uptake mediated by GlyT1.
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Chapter 5: Overall discussion and concluding remarks
In the last decade, the importance of neurotransmitter transporters has risen because new
functions and regulatory pathways have been discovered. This chapter will summarize our
findings and give an overview of how they contribute to the field.
The high-affinity GlyT1 has been proposed to be a good pharmacological target in the
treatment of schizophrenia, which highlights its importance. According to the NIMH, 26% of
Americans at the ages of 18 and older suffer from a diagnosable mental disorder and only 6%
suffer a serious mental illness (NIMH, 2009). In addition, it was estimated that at least 1% of the
population in the United States is or may be affected by schizophrenia (Regier et al., 1993).
Several reports have shown that antagonists of the N-methyl D-aspartate receptor (NMDAr)
produce a psychosis that resembles schizophrenia, suggesting a link between the NMDAr
dysfunction and schizophrenia (Kristal et al., 1994). In previous years, the theory of NMDAr
hypo-function as the molecular defect in schizophrenia had acquired great acceptance. As
previously reported, enhancement of NMDAr activity may work as a treatment for schizophrenic
patients (Shim et al., 2008). However, NMDAr activation by glutamate agonists has been
discarded due to neurotoxic side effects and several research groups have focused on the glycinebinding site of the NMDAr as a way of modulating NMDAr activity without side effects. This
idea supports the role of GlyT1 as a regulator of NMDAr activity, given that it regulates
significant amounts of glycine available for the receptor. NMDAr and GlyT1 are expressed in
the same brain areas, and the discovery of new drugs that inhibit GlyT1 have made it possible to
improve some of the schizophrenia symptoms with less or no-side effects, in comparison with
the regular antipsychotics used to treat schizophrenic patients (Smith et al., 1992; Tsai et al.,
2004). Moreover, high-activity of NMDAr improves memory, as it was shown in animal models
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either by inhibition or knockout of the GlyT1 (GlyT1+/-), which strongly re-enforce the idea that
NMDAr activity is modulated by the GlyT1 (Gomeza et al., 2003; Tsai et al., 2004; Gabernet et
al., 2005). Taking these findings together, we considered it to be necessary to investigate the
mechanism of regulation of GlyT1 activity, and how this modulation function. Similar to other
members of the SLC6 family, it seems that GlyT1 activity can be downregulated after the
activation of PKC by PMA (Sato et al., 1995). However, PMA cannot be used as a drug for
downregulation of the GlyT1 activity because it is a potent tumor promoter and activates
different PKCs. Moreover, inhibitors of GlyT1 may not be of much help because GlyT1 is
essential for glycinergic neurotransmission and the homozygote GlyT1-knochout mice (GlyT1-/-)
died a few days after birth. Therefore, understanding the mechanism of regulation for the GlyT1
seems to be very promising in terms of drug discovery and pharmacological interventions in the
NMDA receptor related diseases. However, important aspects of the GlyT1-regulation with PKC
have been poorly investigated such as phosphorylation of the GlyT1 and their function.
Experiments and data described in chapter 2 revealed that GlyT1a, b and c are phosphorylated in
a PKC- and time-dependent fashion. In addition, pharmacological and biochemical approaches
revealed that phosphorylation of PKC involve a single conventional PKCβ isoenzyme.
Moreover, immunoblotting experiments disclosed that serine and threonine but, not tyrosine
residues are the sites for PKCβ-dependent phosphorylation. On the other hand, downregulation
of glycine uptake seems to be a more complicated process, because the two conventional PKCα
and β isoenzymes are implicated in regulation of activity. Site-directed mutagenesis of serine and
threonine residues at either N- or C-terminus revealed that both terminal ends were
phosphorylated during our assays. Regarding the role of phosphorylation on transporter function,
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it is possible that phosphorylation may be regulating the GlyT1 activity in some way or be a part
of a signal to modulate the GlyT1 trafficking.
In addition to phosphorylation of the GlyT1, we generated a model of the GlyT1b based
on the three-dimensional structure of LeuT. Because GlyT1 is considered to be an important
pharmacological target, a model of three-dimensional structure should be helpful to study
structure-function relationships, such as mapping the substrates binding sites and translocation
pathway. This information should be relevant in future drug design and pharmacological work.
This model is provides a framework for future site-directed mutagenesis studies that should
validate this model.
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